{
    "clinical_study": {
        "@rank": "142845", 
        "acronym": "VELVET", 
        "arm_group": {
            "arm_group_label": "OPTIMOX-aflibercept", 
            "arm_group_type": "Experimental", 
            "description": "Induction therapy (sequence #1)\nRegimen : aflibercept + modified FOLFOX7\nDuration : 6 cycles (3 months) Maintenance after induction (sequence #2) First phase (sequence #2A)\nRegimen : aflibercept + fluoropyrimidine (simplifed LV5FU2 or capecitabine)\nDuration : 6 cycles (3 months) Second phase (sequence #2B)\nRegimen : aflibercept +/- fluoropyrimidine (simplifed LV5FU2 or capecitabine) according to eligibility criteria for chemotherapy-free interval)\nDuration : until PD or limiting toxicity Reintroduction (sequence #3)\nRegimen : aflibercept + modified FOLFOX7\nDuration : 6 cycles (3 months) Maintenance after reintroduction (sequence #4)\nRegimen : aflibercept + fluoropyrimidine\nDuration : until PD or limiting toxicity"
        }, 
        "brief_summary": {
            "textblock": "Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than\n      a continuous administration of chemotherapy until progression, in order to decrease the risk\n      of severe toxicities."
        }, 
        "brief_title": "OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Unresectable Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The addition of aflibercept to the standard FOLFIRI regimen as second-line therapy was\n      evaluated in a large phase III study (EFC10262-VELOUR). This new combination significantly\n      improved both PFS (4.7 to 6.9 months, HR=0.76; P=.00007) and OS (12.1 to 13.5 months,\n      HR=0.82; P=.0032). In the evaluable population (86.5%), the tumor response rate was also\n      improved when adding aflibercept (ORR=19.8% [16.4-23.2]) to the FOLFIRI regimen (ORR=11.1%\n      [8.5-13.8]).\n\n      This trial will evaluate the feasibility of adding aflibercept to an oxaliplatin-based\n      regimen as a first-line therapy , using the OPTIMOX strategy rather than a continuous\n      administration of chemotherapy until progression, in order to decrease the risk of severe\n      toxicities."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed and dated informed consent, and willing and able to comply with protocol\n             requirements,\n\n          2. Histologically proven adenocarcinoma of the colon and/or rectum,\n\n          3. Metastatic disease confirmed,\n\n          4. No prior therapy for metastatic disease (in case of previous adjuvant therapy,\n             interval from end of chemotherapy to relapse must be >6 months for fluoropyrimidine\n             alone or >12 months for oxaliplatin-based, bevacizumab-based, cetuximab-based\n             therapy,\n\n          5. Duly documented inoperable metastatic disease, ie not suitable for complete\n             carcinological surgical resection,\n\n          6. At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic\n             Resonance Imaging) according to RECIST v1.1,\n\n          7. Age \u226518 years,\n\n          8. ECOG Performance status (PS) 0-2,\n\n          9. Hematological status: neutrophils (ANC) \u22651.5x109/L; platelets \u2265100x109/L; haemoglobin\n             \u22659g/dL,\n\n         10. Adequate renal function: serum creatinine level <150\u00b5M,\n\n         11. Adequate liver function: serum bilirubin \u22643 x upper normal limit (ULN), alkaline\n             phosphatase <5xULN,\n\n         12. Proteinuria <2+ (dipstick urinalysis) or \u22641g/24hour,\n\n         13. Baseline evaluations: clinical and blood evaluations performed no more than 2 weeks\n             (14 days) prior to confirmation of eligibility, tumor assessment (chest X ray,\n             CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days)\n             prior to confirmation of eligibility,\n\n         14. For female patients of childbearing potential, negative serum or urine pregnancy test\n             within 1 week (7 days) prior of starting study treatment,\n\n         15. Female patients of childbearing potential must commit to using reliable and effective\n             methods of contraception during the trial and until at least six months after the end\n             of study treatment. Females are neither pregnant nor in breastfeeding. Male patients\n             with a partner of childbearing potential must agree to use effective contraception in\n             addition to the contraceptive method used by their partner during the trial and until\n             at least six months after the end of study treatment.\n\n         16. Registration in a national health care system (CMU included for France).\n\n        Exclusion Criteria:\n\n          1. History or evidence upon physical examination of CNS metastasis unless adequately\n             treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard\n             medical therapy),\n\n          2. Exclusive bone metastasis,\n\n          3. Uncontrolled hypercalcemia,\n\n          4. Pre-existing permanent neuropathy (NCI grade \u22652),\n\n          5. Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or\n             diastolic blood pressure >100 mmHg despite optimal medical therapy), or history of\n             hypertensive crisis, or hypertensive encephalopathy,\n\n          6. Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted\n             therapy, immunotherapy/ radio-immunotherapy),\n\n          7. Treatment with any other investigational medicinal product within 28 days prior to\n             study entry,\n\n          8. Other serious and uncontrolled non-malignant disease,\n\n          9. Other concomitant or previous malignancy, except: i/ adequately treated in-situ\n             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,\n             iii/ cancer in complete remission for >5 years,\n\n         10. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic\n             injury within the last 28 days\n\n         11. Patients with known allergy to any excipient to study drugs,\n\n         12. History of myocardial infarction and/or stroke within 6 months prior to study entry,\n\n         13. Bowel obstruction."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "49", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802684", 
            "org_study_id": "VELVET C12-1", 
            "secondary_id": "2012-003521-25"
        }, 
        "intervention": {
            "arm_group_label": "OPTIMOX-aflibercept", 
            "description": "Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)", 
            "intervention_name": "aflibercept", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "unresectable", 
            "metastatic", 
            "colorectal", 
            "cancer", 
            "OPTIMOX", 
            "aflibercept"
        ], 
        "lastchanged_date": "August 27, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "C\u00e9dric Lecaille, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33300"
                    }, 
                    "name": "Polyclinique de Bordeaux Nord"
                }, 
                "investigator": {
                    "last_name": "C\u00e9dric Lecaille, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christophe Tournigand, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cr\u00e9teil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "H\u00f4pital Henri Mondor"
                }, 
                "investigator": {
                    "last_name": "Christophe Tournigand, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Val\u00e9rie Lebrun-Ly, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France", 
                        "zip": "87042"
                    }, 
                    "name": "CHU Dupuytren"
                }, 
                "investigator": {
                    "last_name": "Val\u00e9rie Lebrun-Ly, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "J\u00e9rome Desrame, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69008"
                    }, 
                    "name": "H\u00f4pital Priv\u00e9 Jean Mermoz"
                }, 
                "investigator": {
                    "last_name": "J\u00e9r\u00f4me Desrame, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dominique Auby, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "40000"
                    }, 
                    "name": "CH Mont de Marsan"
                }, 
                "investigator": {
                    "last_name": "Dominique Auby, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Benoist Chibaudel, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75012"
                    }, 
                    "name": "H\u00f4pital Saint-Antoine"
                }, 
                "investigator": {
                    "last_name": "Benoist Chibaudel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christophe Louvet, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75014"
                    }, 
                    "name": "Institut Mutualiste Montsouris"
                }, 
                "investigator": {
                    "last_name": "Christophe Louvet, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ga\u00ebl Deplanque, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75013"
                    }, 
                    "name": "H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re"
                }, 
                "investigator": {
                    "last_name": "Ga\u00ebl Deplanque, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study.", 
        "overall_contact": {
            "last_name": "Benoist Chibaudel, MD", 
            "phone": "+0033 1 49 28 20 00"
        }, 
        "overall_official": {
            "affiliation": "H\u00f4pital Saint Antoine", 
            "last_name": "Benoist Chibaudel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: ANSM - French Competent Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival at 6 months", 
            "safety_issue": "No", 
            "time_frame": "time interval from inclusion to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed at 6 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Median Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "time interval from inclusion to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed up to 3 years after the beginning of the study"
            }, 
            {
                "description": "DDC excludes:\nIntervals between disease progression and re-initiation of treatment,\nPFS of inactive treatment if PD occurs at first evaluation after treatment re-initiation", 
                "measure": "duration of disease control (DDC)", 
                "safety_issue": "No", 
                "time_frame": "sum of PFS of each active treatment course. Assessed up to 3 years after the beginning of the study"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "time interval from inclusion to the date of death from any cause. Assessed up to 3 years after the beginning of the study."
            }, 
            {
                "description": "assessed using RECIST version 1.1 per sequence of therapy.", 
                "measure": "tumor Response Rate (RR)", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 2 months during treatment period (- Estimated treatment duration per patient : 16 months)."
            }, 
            {
                "description": "EORTC QLQ C-30", 
                "measure": "Health related Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Assessed from study entry to 1 month after last study drug administration and up to 3 years after the beginning of the study."
            }, 
            {
                "description": "The study will take into account all adverse events observed during and after drug administration, with a particular interest for:\nAny AE\nAny AE related to study treatment\nAny serious AE\nAny serious AE related to study treatment\nAny NCI-CTC grade 3 or 4 AE\nAny NCI-CTC grade 3 or 4 AE related to study treatment\nAny AE causing discontinuation of study treatment\nAny AE causing discontinuation of selected treatment only\nAny AE related to study treatment causing discontinuation\nAny AE causing a dose reduction of study medication\nAny AE leading to death\nAny AE related to study treatment leading to death.", 
                "measure": "Safety", 
                "safety_issue": "No", 
                "time_frame": "Assessed from study entry  to 1 month after last study drug administration, assessed up to 3 years after the beginning of the study"
            }, 
            {
                "description": "The number of patient with R0 and R1 curative salvage surgery will be assessed globally and per sequence of therapy.", 
                "measure": "Curative salvage surgery", 
                "safety_issue": "No", 
                "time_frame": "assessed up to 3 years after the beginning of the study"
            }
        ], 
        "source": "Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}